Corium International Inc. (NASDAQ:CORI) shares shot up 4.5% on Wednesday . The stock traded as high as $4.80 and last traded at $4.67, with a volume of 53,974 shares. The stock had previously closed at $4.47.

Several research firms have weighed in on CORI. Zacks Investment Research upgraded Corium International from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, July 19th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Corium International in a research note on Thursday, June 23rd. FBR & Co reaffirmed a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Leerink Swann reaffirmed a “buy” rating and issued a $14.00 target price on shares of Corium International in a research report on Wednesday, May 18th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Corium International in a research report on Wednesday, May 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $11.58.

The stock’s 50 day moving average is $3.92 and its 200 day moving average is $4.46. The company’s market capitalization is $104.08 million.

Corium International (NASDAQ:CORI) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. On average, equities analysts predict that Corium International Inc. will post ($1.70) EPS for the current year.

In other Corium International news, Director Eric Bjerkholt purchased 24,500 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The shares were acquired at an average price of $3.64 per share, with a total value of $89,180.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

A hedge fund recently raised its stake in Corium International stock. Turner Investments L.P. boosted its stake in shares of Corium International Inc. (NASDAQ:CORI) by 97.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 197,520 shares of the biopharmaceutical company’s stock after buying an additional 97,520 shares during the period. Turner Investments L.P. owned 0.89% of Corium International worth $1,604,000 as of its most recent filing with the SEC.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.